CN104768965B - 齐墩果酸的c17-杂芳基衍生物和其使用方法 - Google Patents

齐墩果酸的c17-杂芳基衍生物和其使用方法 Download PDF

Info

Publication number
CN104768965B
CN104768965B CN201380057684.2A CN201380057684A CN104768965B CN 104768965 B CN104768965 B CN 104768965B CN 201380057684 A CN201380057684 A CN 201380057684A CN 104768965 B CN104768965 B CN 104768965B
Authority
CN
China
Prior art keywords
compound
disease
pharmaceutically acceptable
compounds
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380057684.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN104768965A (zh
Inventor
江昕
克里斯多福·F·班德
麦琳·维斯尼克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Reata Pharmaceuticals Inc
Original Assignee
Reata Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reata Pharmaceuticals Inc filed Critical Reata Pharmaceuticals Inc
Publication of CN104768965A publication Critical patent/CN104768965A/zh
Application granted granted Critical
Publication of CN104768965B publication Critical patent/CN104768965B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/101,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J63/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008Expansion of ring D by one atom, e.g. D homo steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Lubricants (AREA)
  • Steroid Compounds (AREA)
  • Epidemiology (AREA)
CN201380057684.2A 2012-09-10 2013-09-10 齐墩果酸的c17-杂芳基衍生物和其使用方法 Active CN104768965B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261699199P 2012-09-10 2012-09-10
US61/699,199 2012-09-10
PCT/US2013/059015 WO2014040056A1 (en) 2012-09-10 2013-09-10 C17-heteroaryl derivatives of oleanolic acid and methods of use thereof

Publications (2)

Publication Number Publication Date
CN104768965A CN104768965A (zh) 2015-07-08
CN104768965B true CN104768965B (zh) 2018-05-11

Family

ID=49253401

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380057684.2A Active CN104768965B (zh) 2012-09-10 2013-09-10 齐墩果酸的c17-杂芳基衍生物和其使用方法

Country Status (28)

Country Link
US (1) US20140088163A1 (cg-RX-API-DMAC7.html)
EP (1) EP2892911B1 (cg-RX-API-DMAC7.html)
JP (1) JP6272870B2 (cg-RX-API-DMAC7.html)
KR (1) KR102237364B1 (cg-RX-API-DMAC7.html)
CN (1) CN104768965B (cg-RX-API-DMAC7.html)
AU (1) AU2013312102B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015005200B1 (cg-RX-API-DMAC7.html)
CA (1) CA2882417C (cg-RX-API-DMAC7.html)
CY (1) CY1119762T1 (cg-RX-API-DMAC7.html)
DK (1) DK2892911T3 (cg-RX-API-DMAC7.html)
EA (1) EA029069B1 (cg-RX-API-DMAC7.html)
ES (1) ES2644615T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20171565T1 (cg-RX-API-DMAC7.html)
HU (1) HUE036797T2 (cg-RX-API-DMAC7.html)
IL (1) IL237638B (cg-RX-API-DMAC7.html)
IN (1) IN2015DN01547A (cg-RX-API-DMAC7.html)
LT (1) LT2892911T (cg-RX-API-DMAC7.html)
ME (1) ME02911B (cg-RX-API-DMAC7.html)
MX (1) MX366954B (cg-RX-API-DMAC7.html)
NZ (1) NZ705213A (cg-RX-API-DMAC7.html)
PL (1) PL2892911T3 (cg-RX-API-DMAC7.html)
PT (1) PT2892911T (cg-RX-API-DMAC7.html)
RS (1) RS56563B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201501800UA (cg-RX-API-DMAC7.html)
SI (1) SI2892911T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201700501T1 (cg-RX-API-DMAC7.html)
WO (1) WO2014040056A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201501203B (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3492077A1 (en) 2008-01-11 2019-06-05 Reata Pharmaceuticals, Inc. Synthetic triterpenoids and methods of use in the treatment of disease
AU2009251437B2 (en) 2008-04-18 2014-10-30 Reata Pharmaceuticals, Inc. Compounds including an anti-inflammatory pharmacore and methods of use
WO2009129546A1 (en) 2008-04-18 2009-10-22 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17
EA025568B1 (ru) 2010-12-17 2017-01-30 Рита Фармасьютикалз, Инк. Пиразолильные и пиримидинильные трициклические еноны в качестве антиоксидантных модуляторов воспаления
MX357060B (es) 2012-04-27 2018-06-25 Reata Pharmaceuticals Inc Derivados de 2,2-difluoropropionamida de bardoxolon metilo, formas polimorficas y metodo para su uso de los mismos.
WO2013188818A1 (en) 2012-06-15 2013-12-19 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
UY35023A (es) 2012-09-10 2014-03-31 Reata Pharmaceuticals Inc Derivados c17-alcandiilo y alquendiilo del ácido oleanólico y sus métodos de uso
UY39092A (es) 2013-04-24 2021-03-26 Abbvie Inc Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimórficas y métodos de uso
AU2016219109B2 (en) 2015-02-12 2020-05-14 Reata Pharmaceuticals, Inc. Imidazolyl tricyclic enones as antioxidant iflammation modulators
CA2998681C (en) 2015-09-23 2024-02-06 Reata Pharmaceuticals, Inc. C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses
BR112019009256A2 (pt) 2016-11-08 2019-07-16 Reata Pharmaceuticals Inc métodos para tratar síndrome de alport usando bardoxolona metil ou análogos do mesmo
CN106632574B (zh) * 2016-12-07 2018-05-29 广东天键生物科技有限公司 一种化合物、其制备方法及用途
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制RORγ及其他用途的嘧啶三環烯酮衍生物
MX2020002883A (es) 2017-09-14 2020-10-05 Phoenix Biotechnology Inc Método y composiciones para tratar la infección viral.
AU2018334467B2 (en) 2017-09-14 2022-10-20 Phoenix Biotechnology, Inc. Method and improved neuroprotective composition for treating neurological conditions
IL322405A (en) 2018-06-15 2025-09-01 Reata Pharmaceuticals Inc Decahydro-2h-naphth[1,2-d]imidazole compounds for inhibition of IL-17 and ROR-gamma
US12060340B2 (en) 2018-06-20 2024-08-13 Reata Pharmaceuticals, Inc Cysteine-dependent inverse agonists of nuclear receptors ROR-gamma/ROR-gamma-t and methods of treating diseases or disorders therewith
JP2022501445A (ja) * 2018-09-28 2022-01-06 スーチョワン ハイスコ ファーマスーティカル カンパニー リミテッドSichuan Haisco Pharmaceutical Co., Ltd. テルペノイド誘導体及びその用途
CN114641483B (zh) * 2019-07-19 2024-12-06 里亚塔医药公司 C17极性的-取代的杂芳族合成三萜类化合物及其使用方法
EP4295854A3 (en) 2020-03-31 2024-04-03 Phoenix Biotechnology, Inc. Method and compositions for treating coronavirus infection
RU2020130238A (ru) 2020-03-31 2022-03-14 Феникс Байотекнолоджи, Инк. Способ и композиции для лечения коронавирусной инфекции
JP7214696B2 (ja) * 2020-10-01 2023-01-30 一般財団法人 化学物質評価研究機構 新規in vitro皮膚感作性試験法
WO2022126129A1 (en) 2020-12-11 2022-06-16 Reata Pharmaceuticals, Inc. Synthetic triterpenoids for use in therapy
AU2022208727A1 (en) 2021-01-18 2023-08-03 Reata Pharmaceuticals, Inc. Synthetic ursolic acid derivatives and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102066398A (zh) * 2008-04-18 2011-05-18 里亚塔医药公司 抗氧化剂炎症调节剂:c-17同系化齐墩果酸衍生物
CN102164941A (zh) * 2008-04-18 2011-08-24 里亚塔医药公司 抗氧化剂炎症调节剂:具有饱和c环的齐墩果酸衍生物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326507B1 (en) * 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
CA2485565A1 (en) * 2002-05-13 2004-08-05 Trustees Of Dartmouth College Inhibitors and methods of use thereof
EP3492077A1 (en) 2008-01-11 2019-06-05 Reata Pharmaceuticals, Inc. Synthetic triterpenoids and methods of use in the treatment of disease
WO2009129546A1 (en) * 2008-04-18 2009-10-22 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17
TW201004627A (en) 2008-04-18 2010-02-01 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: novel derivatives of oleanolic acid
BR112013023174B1 (pt) * 2011-03-11 2021-09-21 Reata Pharmaceuticals, Inc Compostos derivados de triterpenoide de c4-monometila e composição farmacêutica compreendendo os referidos compostos
WO2013188818A1 (en) * 2012-06-15 2013-12-19 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102066398A (zh) * 2008-04-18 2011-05-18 里亚塔医药公司 抗氧化剂炎症调节剂:c-17同系化齐墩果酸衍生物
CN102164941A (zh) * 2008-04-18 2011-08-24 里亚塔医药公司 抗氧化剂炎症调节剂:具有饱和c环的齐墩果酸衍生物

Also Published As

Publication number Publication date
CN104768965A (zh) 2015-07-08
US20140088163A1 (en) 2014-03-27
WO2014040056A1 (en) 2014-03-13
AU2013312102A1 (en) 2015-03-12
IL237638A0 (en) 2015-04-30
SMT201700501T1 (it) 2017-11-15
KR20150053982A (ko) 2015-05-19
CA2882417C (en) 2021-04-20
IN2015DN01547A (cg-RX-API-DMAC7.html) 2015-07-03
ES2644615T3 (es) 2017-11-29
NZ705213A (en) 2018-07-27
JP2015529227A (ja) 2015-10-05
ZA201501203B (en) 2021-08-25
ME02911B (me) 2018-10-20
CY1119762T1 (el) 2018-06-27
DK2892911T3 (en) 2017-10-23
EA201590539A1 (ru) 2015-08-31
HUE036797T2 (hu) 2018-07-30
EA029069B1 (ru) 2018-02-28
MX2015003078A (es) 2015-07-14
BR112015005200A2 (cg-RX-API-DMAC7.html) 2017-08-15
BR112015005200B1 (pt) 2022-07-05
CA2882417A1 (en) 2014-03-13
SI2892911T1 (sl) 2017-12-29
PT2892911T (pt) 2017-11-02
KR102237364B1 (ko) 2021-04-06
HRP20171565T1 (hr) 2017-12-15
JP6272870B2 (ja) 2018-01-31
PL2892911T3 (pl) 2018-03-30
AU2013312102B2 (en) 2018-03-08
IL237638B (en) 2020-04-30
HK1211295A1 (en) 2016-05-20
SG11201501800UA (en) 2015-04-29
EP2892911A1 (en) 2015-07-15
LT2892911T (lt) 2017-11-10
EP2892911B1 (en) 2017-08-30
MX366954B (es) 2019-07-31
RS56563B1 (sr) 2018-02-28

Similar Documents

Publication Publication Date Title
CN104768965B (zh) 齐墩果酸的c17-杂芳基衍生物和其使用方法
US11406648B2 (en) C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
CN104955833B (zh) 齐墩果酸的c17-烷二基与烯二基衍生物及其使用方法
US9278912B2 (en) C13-hydroxy derivatives of oleanolic acid and methods of use thereof
CN103619866B (zh) C4-一甲基三萜系化合物的衍生物及其使用方法
WO2013188818A1 (en) A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
HK1211295B (en) C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
HK1212355B (zh) 齐墩果酸的c17-烷二基与烯二基衍生物及其使用方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1211295

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1211295

Country of ref document: HK